Keywords: cv, thera, initiates, cvt-3619, trial, usa-based, therapeutics

CV Thera initiates CVT-3619 trial

Article | 08 September 2008

Print This

USA-based CV Therapeutics has enrolled the first patient in a Phase I trial of CVT-3619, a partial A1 adenosine receptor ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in